Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gallagher

Showing results (191-200 of 210) with videos related to

Pageof 21
Sort By:
Plos Pathogens|May 3, 2014
Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunityStephanie Ascough, Rebecca J Ingram, Karen K Chu, et al.
Breast Cancer Research : BCR|June 13, 2024
Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019Jenna Bhimani, Kelli O'Connell, Isaac J Ergas, et al.
Breast Cancer Research and Treatment|July 6, 2025
Patient characteristics associated with conventional schedule vs. dose dense chemotherapy in women with stage I-IIIA breast cancerJenna Bhimani, Peng Wang, Grace B Gallagher, et al.
JCO Clinical Cancer Informatics|April 18, 2024
Methodology for Using Real-World Data From Electronic Health Records to Assess Chemotherapy Administration in Women With Breast CancerJenna Bhimani, Kelli O'Connell, Isaac J Ergas, et al.
International Journal of Cancer|June 2, 2025
Patient factors and modifications to intended chemotherapy for women with Stages I-IIIA breast cancerJenna Bhimani, Peng Wang, Grace B Gallagher, et al.
Aerospace Medicine and Human Performance|September 10, 2021
Bellagio II Report: Terrestrial Applications of Space Medicine ResearchMarian B Sides, Smith L Johnston, Adam Sirek, et al.
Cancer|March 11, 2026
The landscape of chemotherapy modifications among women treated for stage I-IIIA breast cancerJenna Bhimani, Kelli O'Connell, Victoria S Blinder, et al.
NPJ Breast Cancer|October 30, 2025
Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancerJenna Bhimani, Kelli O'Connell, Grace B Gallagher, et al.
International Journal of Cancer|July 6, 2024
Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I-IIIA breast cancerJenna Bhimani, Kelli O'Connell, Sonia Persaud, et al.
Journal of the National Cancer Institute|November 3, 2025
Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancerErin J Aiello Bowles, Kelli O'Connell, Jenna Bhimani, et al.
Pageof 21

Showing results (191-200 of 210) with videos related to

Sort By:
Pageof 21
Plos Pathogens|May 3, 2014
Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunityStephanie Ascough, Rebecca J Ingram, Karen K Chu, et al.
Breast Cancer Research : BCR|June 13, 2024
Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019Jenna Bhimani, Kelli O'Connell, Isaac J Ergas, et al.
Breast Cancer Research and Treatment|July 6, 2025
Patient characteristics associated with conventional schedule vs. dose dense chemotherapy in women with stage I-IIIA breast cancerJenna Bhimani, Peng Wang, Grace B Gallagher, et al.
JCO Clinical Cancer Informatics|April 18, 2024
Methodology for Using Real-World Data From Electronic Health Records to Assess Chemotherapy Administration in Women With Breast CancerJenna Bhimani, Kelli O'Connell, Isaac J Ergas, et al.
International Journal of Cancer|June 2, 2025
Patient factors and modifications to intended chemotherapy for women with Stages I-IIIA breast cancerJenna Bhimani, Peng Wang, Grace B Gallagher, et al.
Aerospace Medicine and Human Performance|September 10, 2021
Bellagio II Report: Terrestrial Applications of Space Medicine ResearchMarian B Sides, Smith L Johnston, Adam Sirek, et al.
Cancer|March 11, 2026
The landscape of chemotherapy modifications among women treated for stage I-IIIA breast cancerJenna Bhimani, Kelli O'Connell, Victoria S Blinder, et al.
NPJ Breast Cancer|October 30, 2025
Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancerJenna Bhimani, Kelli O'Connell, Grace B Gallagher, et al.
International Journal of Cancer|July 6, 2024
Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I-IIIA breast cancerJenna Bhimani, Kelli O'Connell, Sonia Persaud, et al.
Journal of the National Cancer Institute|November 3, 2025
Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancerErin J Aiello Bowles, Kelli O'Connell, Jenna Bhimani, et al.
Pageof 21